Biotechnology

Skin care

KEYWORDS

epigenetics;

RNA interference (RNAi);

microRNAs;

antagomiRs, mimics


peer-reviewed

Communicating with Skin Cells Using RNA-Based Instructions to Improve Skin Health

Paul Lawrence1, Joseph Ceccoli2

1. Executive Director of Bioscience Research, Discovery, and Scientific Communications at Biocogent, LLC, and Senior Associate Editor, Journal of Cosmetic Science

2. Co-author, President and Founder of Biocogent, LLC

ABSTRACT: The design, development, and deployment of active ingredients for cosmetic care has historically followed a singular strategy: apply a substance to prevent and/or repair damage to skin. This article will discuss an alternative with considerable efficacy that has been devised: utilize RNA-based messages to instruct skin cells on how to restore epigenetic and physiological balance to skin tissue. While small non-coding RNAs have been utilized as diagnostic markers, more groups are investigating their application as a new active ingredient that trusts our skin cells to be more efficacious at implementing strategies to prevent and repair damaged tissue than we are. Here, RNA constructs are topically applied to modulate specific gene expression in a direction supportive of healthy skin physiology. This strategy represents a significant paradigm shift for developing active materials for cosmetic care.

Introduction

Introduction

The cosmetic care industry has employed all four major classes of biological molecules to affect improvements in skin health, which includes carbohydrates, lipids, peptides/proteins, and nucleic acids. The latter category comprising deoxyribonucleic acid (DNA) and its more ancient cousin ribonucleic acid (RNA) have been used in cosmetic care for longer than most are aware, going back many decades.


Molecular biologists posit that RNA may have been the first biological molecule to evolve on Earth due its numerous structural forms and functionalities that have been discovered to date. Indeed, there are approximately 50 different varieties that exist in nature varying in size, structure, and activity. These include, but are not limited to: messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), telomerase RNA (telRNA), ribozymes, small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA). Collectively, the notion that there was a period in Earth’s history where many biological mechanisms were being promulgated by a diverse array of RNA molecules has been termed the “RNA World Hypothesis” (1). As time moves forward, more and more evidence has been amassed to support these contentions suggesting that we are far from plateauing with regard to RNA discovery.


A powerful example of one of the many forms of RNA is represented in the small non-coding RNAs (ncRNAs) that leverage an epigenetic mechanism known as RNA interference (RNAi) or more generally post-transcriptional gene silencing (PTGS), which toggles the expression of specific genes without any alteration to the genetic code (2), (3), (4). These small ncRNAs come in two varieties: short interfering RNAs (siRNAs) and microRNAs (miRNAs or miRs) (5). To understand their roles, it is important to remember biology lessons from early education, specifically the “central dogma of biology” governing how genetic information is molecularly transmitted during the process of gene expression. Segments of DNA sequence encoding particular proteins are used as a template for the construction of a mRNA molecule through a process known as transcription. The mRNA subsequently exits the cell nucleus to rendezvous with ribosomes that are themselves built mostly from rRNA. At these protein factories, translation occurs where the mRNA engages with tRNA that come tethered with different amino acids which are donated to a growing peptide chain that will eventually fold into a functional protein. The siRNAs and miRNAs “interfere” with translation by intercepting the mRNA before it can dock at a ribosome, thus decreasing the production of specific proteins. This article will focus on the application of this process for modern cosmetic care.

Discussion

The History

As described in the Introduction, there is an established history of RNA-based materials being formulated into cosmetic care products dating all the way back to the 1970s and 1980s. While there are no existing scientific publications to cite that investigated the purported benefits of these products, patent records do establish that these were real innovations for the time. The most notable example is a luxury, moisturizing cream called Rejuvenex® that was explicitly marketed as containing RNA as one of its primary active ingredients. Indeed, Rejuvenex® continues to be sold, though the RNA has since been replaced with polydeoxyribonucleotides (PDRNs) harvested from fish.


The New Technology

While RNA was being utilized as an active ingredient in cosmetic care products going back decades, the specific application of using small ncRNAs (siRNAs and miRNAs) to restore epigenetic homeostasis in skin tissue only started being explored around 2013 (6). These “interventionist” uses of siRNA and miRNA molecules have been embodied in constructs known as “mimics” and “antagomiRs” that serve as the “ying and yang” for modulating the expression of particular genes upwards and downwards (7), (8).


Mimics are small ncRNAs that are replicas of endogenous miRNAs. The intention behind their topical deployment is to bolster the existing levels of a specific, naturally occurring miRNA so as to augment its suppression of its targeted downstream gene pathways (7). Here, an increase in the miRNA concentration will result in diminished synthesis of the proteins that are part of that gene pathway. An excellent example of this approach would be to apply a mimic of miR-330-5p, a miRNA that targets the expression of tyrosinase (key enzyme in melanogenesis), which would culminate in reduced production of melanin leading to a skin brightening effect (9).


Alternatively, antagomiRs are small ncRNAs that will intercept specific cellular miRNAs before they can prevent a mRNA from associating with ribosomes, thus contributing to increased production of proteins that are targeted for diminishment by that particular miRNA (8). Topical application of antagomiRs that would interact with miR-29a-3p would be beneficial as they would strengthen the extracellular matrix (ECM) since this miRNA becomes dysregulated as we age leading to decreased synthesis of critical fiber proteins including: type I collagen, elastin, and fibrillin (10). This miRNA and others that interfere with mRNAs reaching the ribosome for these fiber proteins have rightfully been given the moniker of the “wrinkle miRNAs”.


The Success of the Application

Many groups within the cosmetic care industry have been investigating the utilization of mimics and antagomiRs as active ingredients. Each group seems to have a favorite set of skin-relevant miRNAs that they believe will facilitate the return of certain gene expression pathways to normal homeostatic levels that promote and support healthy skin. These different miRNA pathways are described to influence inflammation, reactive oxygen species, ultraviolet-induced damage, mitochondrial health, skin brightening, and certain aspects of skin aging. Some examples are shown with potential cosmetic care application in Table 1.


Table 1. Examples of miRNA pathways being explored for beneficial effects on skin. (10) (11) (12) (9) (13)

As mentioned above, much of the progress in this area has been with diagnostic applications of this technology, where alterations in relative miRNA abundances have been linked to certain skin conditions and the efficacy of specific topical solutions. But the interventionist approach involving topical deployment of RNA-based constructs has enjoyed a slow, percolating enthusiasm with exciting research findings to support its widespread deployment.


The emergence of these active ingredients in cosmetic care represents more than a passing scientific trend, rather it signals a broader evolution towards precision-guided, biologically intelligent skin interventions. As advances in delivery systems and epigenetic research continues to expand, the industry is increasingly well-positioned to move toward approaches capable of subtly influencing the molecular pathways that underlie pigmentation, inflammation, barrier integrity, and visible skin aging (Table 1). The growing experimental evidence and commercial interest unmistakably suggest that momentum is building. In many respects, RNA-based technologies now occupy the same inflection point once seen with peptides, probiotics, and exosomes; emerging platforms transcending from theoretic promise to credible scientifically driven innovation.


According to Mintel reports, there are multiple companies in the cosmetic care industry that have begun to explore this technology. Among the emerging directions attracting attention within cosmetic innovation, targeted miRNA modulation has been identified by Mintel as an area of growing interest. This form of miRNA-based cosmetic care is situated at the intersection of several rapidly advancing scientific fields. It is not an isolated innovation, but rather the product of multiple technologies maturing simultaneously; including, but certainly not limited to epigenetics and skin longevity, delivery technologies, precision “-omics”, advanced active ingredients, and clinical/consumer drivers (Figure 1). The convergence of these disciplines is moving the industry from conventional topical care to precision molecular cosmetics.


Figure 1. miRNA-based cosmetics represent a convergence and maturation of multiple scientific disciplines driving new, innovative solutions for improving and sustaining skin health.

Conclusions

In summary, the emerging roles of miRNAs and siRNAs in topical skin care solutions represent a powerful paradigm shift in the cosmetic care industry. Rather than introduce chemical cocktails to contribute to skin health, epigenetic messages can be sent to remind skin cells that they are exquisitely capable of maintaining healthy tissue by their own means.


Indeed, these new active ingredients shift skin care toward molecular precision, where new strategies to improve and support skin health can be unlocked. From reducing inflammation to fine-tuning cellular repairs, the possibilities being opened by this new approach portend an exciting future of more targeted, effective, and personalized active ingredients.


About the Author

Dr. Paul Lawrence received his doctorate in molecular microbiology from Stony Brook University and before that obtained his Bachelor of Science degree in molecular biology from the University of New Mexico. During his career, he has conducted biological research in academia, industry, and for the United States government. He has executed anti-viral therapeutic and vaccine research projects at Brookhaven National Laboratory and the Plum Island Animal Disease Center. In industry, he has participated in contract biopharmaceutical projects for the former Collaborative Bioalliance as well as Dow Chemical. Dr. Lawrence was also the Director of DNA Production for the anti-counterfeiting biotechnology company, Applied DNA Sciences. Currently, he is the Executive Director of Bioscience Research, Discovery, and Scientific Communications for Biocogent, a developer and manufacturer of bio-active ingredients with cosmetic care applications. In his spare time, he is also an adjunct professor at three different colleges teaching microbiology to future nurses, doctors, and cosmetic care professionals. He also volunteers as the senior associate editor of the Journal of Cosmetic Science and is currently a member of the Certificate Program Task Force for the Society of Cosmetic Chemists (SCC). He has also been an instructor for multiple courses with the SCC’s continuing education program. Over the course of his career, Dr. Lawrence has published more than 40 research manuscripts and review articles, more than 25 online science digests, and has authored a textbook chapter on the molecular pathogenesis of one of the world’s most infectious viruses.

Paul Lawrence

Executive Director of Bioscience Research, Discovery, and Scientific Communications at Biocogent, LLC, and Senior Associate Editor, Journal of Cosmetic Science.

Joseph Ceccoli is the Founder, President, and CEO of Biocogent, LLC, a bioscience company focused on developing and commercializing innovative skin-active molecules and treatment technologies for the personal care, medical care, and cosmetic industries. With more than three decades of experience in specialty chemicals and biotechnology, he previously served as Global Director of Operations at BASF Corporation, overseeing multiple domestic and international business units, and held senior leadership roles at Engelhard Corporation and The Collaborative Group.


Mr. Ceccoli holds a B.S. in Biotechnology from the Rochester Institute of Technology and has advanced training and certifications in pharmaceutical sciences, emulsion chemistry, engineering, and management. He is a long-time member of the American Chemical Society and the Society of Cosmetic Chemists, has authored more than 20 technical papers and holds 16 patents.

Joseph Ceccoli

President and Founder of Biocogent, LLC

References and notes

  1. Fine, J.L. and A.M. Moses, An RNA Condensate Model for the Origin of Life. J Mol Biol, 2025. 437(12): p. 169124. https://www.sciencedirect.com/science/article/pii/S0022283625001901?via%3Dihub
  2. Elbashir, S.M., et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001. 411(6836): p. 494-8. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
  3. Elbashir, S.M., W. Lendeckel, and T. Tuschl, RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev, 2001. 15(2): p. 188-200. https://genesdev.cshlp.org/content/15/2/188
  4. Meister, G. and T. Tuschl, Mechanisms of gene silencing by double-stranded RNA. Nature, 2004. 431(7006): p. 343-9. Mechanisms of gene silencing by double-stranded RNA
  5. Carthew, R.W. and E.J. Sontheimer, Origins and Mechanisms of miRNAs and siRNAs. Cell, 2009. 136(4): p. 642-55. https://linkinghub.elsevier.com/retrieve/pii/S009286740900083X
  6. Lam, J.K., et al., siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids, 2015. 4(9): p. e252. siRNA Versus miRNA as Therapeutics for Gene Silencing - PubMed
  7. Bader, A.G., D. Brown, and M. Winkler, The promise of microRNA replacement therapy. Cancer Res, 2010. 70(18): p. 7027-30. https://aacrjournals.org/cancerres/article/70/18/7027/559655/The-Promise-of-MicroRNA-Replacement
  8. Krutzfeldt, J., et al., Silencing of microRNAs in vivo with 'antagomirs'. Nature, 2005. 438(7068): p. 685-9. Silencing of microRNAs in vivo with ‘antagomirs’
  9. Rambow, F., et al., miR-330-5p targets tyrosinase and induces depigmentation. J Invest Dermatol, 2014. 134(11): p. 2846-2849. https://linkinghub.elsevier.com/retrieve/pii/S0022202X15365453
  10. Gallant-Behm, C.L., et al., A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. J Invest Dermatol, 2019. 139(5): p. 1073-1081. https://linkinghub.elsevier.com/retrieve/pii/S0022202X18328306
  11. Chevalier, F.P., et al., MiR-30a-5p Alters Epidermal Terminal Differentiation during Aging by Regulating BNIP3L/NIX-Dependent Mitophagy. Cells, 2022. 11(5). MiR-30a-5p Alters Epidermal Terminal Differentiation during Aging by Regulating BNIP3L/NIX-Dependent…
  12. Rebane, A., et al., MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes. J Allergy Clin Immunol, 2014. 134(4): p. 836-847 e11. https://linkinghub.elsevier.com/retrieve/pii/S0091674914007350
  13. Wu, D., et al., Mir-434-5p mediates skin whitening and lightening. Clin Cosmet Investig Dermatol, 2008. 1: p. 19-35. https://pmc.ncbi.nlm.nih.gov/articles/PMC3048595/